# IonQ, Inc.: financial statements, quarterly

IONQ · NYSE · CIK 1824920 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ionq.md) · [Financials](/companies/ionq/financials.md) · [Filings](/companies/ionq/filings.md) · [Insiders](/companies/ionq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ionq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.1](/filings/0000950170-24-122305.md) | [6.1 d](/filings/0001193125-26-071562.md) | [7.6](/filings/0000950170-25-065699.md) | [11.4](/filings/0000950170-25-104066.md) | [12.4](/filings/0001193125-25-266942.md) | [11.7 d](/filings/0001193125-26-071562.md) | [7.6](/filings/0001193125-26-211876.md) | [20.7](/filings/0001193125-26-341001.md) | [39.9](/filings/0001193125-25-266942.md) | [61.9 d](/filings/0001193125-26-071562.md) | [64.7](/filings/0001193125-26-211876.md) | [80.1](/filings/0001193125-26-341001.md) |
| Research and development | $m | [24.6](/filings/0000950170-24-122305.md) | [31.6 d](/filings/0001193125-26-071562.md) | [32.4](/filings/0000950170-25-065699.md) | [31.2](/filings/0000950170-25-104066.md) | [33.2](/filings/0001193125-25-266942.md) | [40.1 d](/filings/0001193125-26-071562.md) | [40.0](/filings/0001193125-26-211876.md) | [103](/filings/0001193125-26-341001.md) | [66.3](/filings/0001193125-25-266942.md) | [96.1 d](/filings/0001193125-26-071562.md) | [126](/filings/0001193125-26-211876.md) | [161](/filings/0001193125-26-341001.md) |
| Operating income | $m | [(42.2)](/filings/0000950170-24-122305.md) | [(54.4) d](/filings/0001193125-26-071562.md) | [(52.9)](/filings/0000950170-25-065699.md) | [(48.9)](/filings/0000950170-25-104066.md) | [(53.1)](/filings/0001193125-25-266942.md) | [(77.5) d](/filings/0001193125-26-071562.md) | [(75.7)](/filings/0001193125-26-211876.md) | [(161)](/filings/0001193125-26-341001.md) | [(169)](/filings/0001193125-25-266942.md) | [(229) d](/filings/0001193125-26-071562.md) | [(272)](/filings/0001193125-26-211876.md) | [(337)](/filings/0001193125-26-341001.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122305.md) | [0.0 d](/filings/0001193125-26-071562.md) | [0.0](/filings/0000950170-25-065699.md) | [0.0](/filings/0000950170-25-104066.md) | [0.0](/filings/0001193125-25-266942.md) | [0.0 d](/filings/0001193125-26-071562.md) | [0.0](/filings/0001193125-26-211876.md) | [(15.3)](/filings/0001193125-26-341001.md) | [(4.4)](/filings/0001193125-25-266942.md) | [(24.9) d](/filings/0001193125-26-071562.md) | [(6.4)](/filings/0001193125-26-211876.md) | [(6.1)](/filings/0001193125-26-341001.md) |
| Net income | $m | [(44.8)](/filings/0000950170-24-122305.md) | [(41.9) d](/filings/0001193125-26-071562.md) | [(39.6)](/filings/0000950170-25-065699.md) | [(37.6)](/filings/0000950170-25-104066.md) | [(52.5)](/filings/0001193125-25-266942.md) | [(202) d](/filings/0001193125-26-071562.md) | [(32.3)](/filings/0001193125-26-211876.md) | [(177)](/filings/0001193125-26-341001.md) | [(1,055)](/filings/0001193125-25-266942.md) | [754 d](/filings/0001193125-26-071562.md) | [805](/filings/0001193125-26-211876.md) | [(1,868)](/filings/0001193125-26-341001.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0000950170-24-122305.md) | not reported | [(0.19)](/filings/0000950170-25-065699.md) | [(0.18)](/filings/0000950170-25-104066.md) | [(0.24)](/filings/0001193125-25-266942.md) | not reported | [(0.14)](/filings/0001193125-26-211876.md) | [(0.70)](/filings/0001193125-26-341001.md) | [(3.58)](/filings/0001193125-25-266942.md) | not reported | [2.07](/filings/0001193125-26-211876.md) | [(5.08)](/filings/0001193125-26-341001.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0000950170-24-122305.md) | not reported | [(0.19)](/filings/0000950170-25-065699.md) | [(0.18)](/filings/0000950170-25-104066.md) | [(0.24)](/filings/0001193125-25-266942.md) | not reported | [(0.14)](/filings/0001193125-26-211876.md) | [(0.70)](/filings/0001193125-26-341001.md) | [(3.58)](/filings/0001193125-25-266942.md) | not reported | [2.19](/filings/0001193125-26-211876.md) | [(5.08)](/filings/0001193125-26-341001.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.1](/filings/0000950170-23-061982.md) | [35.7](/filings/0000950170-25-027722.md) | [60.1](/filings/0000950170-24-057804.md) | [41.8](/filings/0000950170-24-092782.md) | [30.2](/filings/0000950170-24-122305.md) | [54.4](/filings/0001193125-26-071562.md) | [160](/filings/0000950170-25-065699.md) | [140](/filings/0000950170-25-104066.md) | [346](/filings/0001193125-25-266942.md) | [1,031](/filings/0001193125-26-341001.md) | [494](/filings/0001193125-26-211876.md) | [1,236](/filings/0001193125-26-341001.md) |
| Current assets | $m | [404](/filings/0000950170-23-061982.md) | [390](/filings/0000950170-25-027722.md) | [410](/filings/0000950170-24-057804.md) | [405](/filings/0000950170-24-092782.md) | [395](/filings/0000950170-24-122305.md) | [379](/filings/0001193125-26-071562.md) | [637](/filings/0000950170-25-065699.md) | [626](/filings/0000950170-25-104066.md) | [1,215](/filings/0001193125-25-266942.md) | [2,586](/filings/0001193125-26-341001.md) | [2,303](/filings/0001193125-26-211876.md) | [2,410](/filings/0001193125-26-341001.md) |
| Total assets | $m | [565](/filings/0000950170-23-061982.md) | [554](/filings/0000950170-25-027722.md) | [544](/filings/0000950170-24-057804.md) | [517](/filings/0000950170-24-092782.md) | [498](/filings/0000950170-24-122305.md) | [508](/filings/0001193125-26-071562.md) | [850](/filings/0000950170-25-065699.md) | [1,347](/filings/0000950170-25-104066.md) | [4,319](/filings/0001193125-25-266942.md) | [6,570](/filings/0001193125-26-341001.md) | [6,694](/filings/0001193125-26-211876.md) | [6,779](/filings/0001193125-26-341001.md) |
| Current liabilities | $m | [28.6](/filings/0000950170-23-061982.md) | [37.2](/filings/0000950170-25-027722.md) | [34.7](/filings/0000950170-24-057804.md) | [30.8](/filings/0000950170-24-092782.md) | [32.3](/filings/0000950170-24-122305.md) | [36.1](/filings/0001193125-26-071562.md) | [48.4](/filings/0000950170-25-065699.md) | [80.6](/filings/0000950170-25-104066.md) | [139](/filings/0001193125-25-266942.md) | [167](/filings/0001193125-26-341001.md) | [164](/filings/0001193125-26-211876.md) | [226](/filings/0001193125-26-341001.md) |
| Total liabilities | $m | [66.9](/filings/0000950170-23-061982.md) | [68.6](/filings/0000950170-25-027722.md) | [64.1](/filings/0000950170-24-057804.md) | [54.2](/filings/0000950170-24-092782.md) | [62.2](/filings/0000950170-24-122305.md) | [125](/filings/0001193125-26-071562.md) | [85.0](/filings/0000950170-25-065699.md) | [168](/filings/0000950170-25-104066.md) | [2,032](/filings/0001193125-25-266942.md) | [2,757](/filings/0001193125-26-341001.md) | [1,704](/filings/0001193125-26-211876.md) | [3,439](/filings/0001193125-26-341001.md) |
| Shareholders' equity | $m | [498](/filings/0000950170-24-122305.md) | [485](/filings/0000950170-25-065699.md) | [480](/filings/0000950170-25-065699.md) | [463](/filings/0000950170-24-122305.md) | [436](/filings/0000950170-24-122305.md) | [384](/filings/0001193125-26-071562.md) | [765](/filings/0000950170-25-065699.md) | [1,162](/filings/0000950170-25-104066.md) | [2,273](/filings/0001193125-25-266942.md) | [3,800](/filings/0001193125-26-341001.md) | [4,976](/filings/0001193125-26-211876.md) | [3,327](/filings/0001193125-26-341001.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.3) d](/filings/0000950170-24-122305.md) | [(26.6) d](/filings/0001193125-26-071562.md) | [(20.5)](/filings/0000950170-25-065699.md) | [(26.6) d](/filings/0000950170-25-104066.md) | [(19.2) d](/filings/0001193125-25-266942.md) | [(39.4) d](/filings/0001193125-26-071562.md) | [(33.0)](/filings/0001193125-26-211876.md) | [(52.6) d](/filings/0001193125-26-341001.md) | [(123) d](/filings/0001193125-25-266942.md) | [(74.5) d](/filings/0001193125-26-071562.md) | [(151)](/filings/0001193125-26-211876.md) | [(104) d](/filings/0001193125-26-341001.md) |
| Capital expenditure | $m | [4.1 d](/filings/0000950170-24-122305.md) | [7.2 d](/filings/0001193125-26-071562.md) | [3.1](/filings/0000950170-25-065699.md) | [7.5 d](/filings/0000950170-25-104066.md) | [3.8 d](/filings/0001193125-25-266942.md) | [3.6 d](/filings/0001193125-26-071562.md) | [2.3](/filings/0001193125-26-211876.md) | [1.2 d](/filings/0001193125-26-341001.md) | [4.1 d](/filings/0001193125-25-266942.md) | [8.8 d](/filings/0001193125-26-071562.md) | [8.4](/filings/0001193125-26-211876.md) | [10.2 d](/filings/0001193125-26-341001.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [198](/filings/0000950170-23-061982.md) | [200](/filings/0000950170-24-057804.md) | [201](/filings/0000950170-24-092782.md) | [203](/filings/0000950170-24-122305.md) | [208](/filings/0000950170-25-065699.md) | [212](/filings/0000950170-25-104066.md) | [214](/filings/0001193125-25-266942.md) | [229](/filings/0001193125-26-211876.md) | [251](/filings/0001193125-26-341001.md) | [295](/filings/0001193125-25-266942.md) | [371](/filings/0001193125-26-211876.md) | [368](/filings/0001193125-26-341001.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 381,002,314 at 2026-07-29, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-341001.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.